Study of alpelisib for insulin resistance
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests a single dose of a drug called alpelisib (a PI3K inhibitor) to see how it affects insulin and blood sugar in people who are either insulin sensitive or insulin resistant. The goal is to understand why some people become resistant to insulin, which may help find new treatments for diabetes and related conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must be able to understand English or Spanish.
- Your body mass index (BMI) should be between 18-25 (if you are insulin sensitive) or 30-45 (if you are insulin resistant).
- If you are in the insulin-sensitive group, you must have normal blood sugar and insulin levels. If you are in the insulin-resistant group, you must have high insulin and signs of prediabetes.
- You cannot have diabetes, certain heart or liver problems, or a history of some weight-loss surgeries.
- You must not be pregnant, breastfeeding, or taking certain medications (like most diabetes drugs or cholesterol drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single dose of a drug called alpelisib to see how it affects body weight and metabolism. It may help researchers understand how the drug could be used for weight-related conditions.
This study tests how your body responds to insulin by using a special test called a pancreatic clamp. It may help researchers understand insulin resistance better and find new ways to treat it.
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
This study tests an experimental drug, ALN-4324, to see if it can improve how your body responds to insulin. It’s for adults with type 2 diabetes who are already on certain diabetes medications and have stable blood sugar control.
This trial tests alpelisib (a targeted medicine) for people who have lymphatic malformations (LyM) that cause symptoms and have a PIK3CA mutation. It may help shrink or control these lesions when other procedures are delayed until after the first 24 weeks.
Hear when a new Insulin Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.